Individualized medication gene testing reagent kit for beta-receptor blocker
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for gene detection and blockers, which is applied in the field of gene detection kits for individualized drug use of β-receptor blockers, and can solve problems such as no response, adverse drug reactions, and affecting treatment effects
Inactive Publication Date: 2019-01-04
中科基因生物科技(江苏)有限公司
View PDF2 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Variations in the CYP2D6 gene can lead to adverse drug reactions or no response to drugs at normal drug doses, thereby affecting the therapeutic effect
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0031] Prepare a gene detection kit for detecting β-receptor blockers for individualized drug use for one person, including the following components:
[0032] (1) 2 pairs of CYP2D6*10 and ADRB1 (1165G>C) site amplification and sequencing primers, each primer 1OD, and the primer sequences are shown in Table 1;
[0036] This kit is stored at -20°C, and repeated freezing and thawing should be avoided as much as possible.
Embodiment 2
[0038] The prepared one-person kit is used for genotyping detection of the gene for individualized drug use of β-blockers, including steps:
[0039] (1) extract the genomic DNA of the sample;
[0040] (2) PCR amplification of CYP2D6*10 and ADRB1 (1165G>C) loci
[0041] For CYP2D6*10 and ADRB1 (1165G>C) sites, design primers according to Table 1 for PCR amplification. Each reaction system has a total volume of 16 μL, including 7.5 μL of Taq enzyme mixture (dNTP, 10×PCR reaction buffer, MgCl 2 ), deionized water 5.5 μL, primer pair (10uM) 1 μL, genomic DNA (100ng / ul) 1ul. The reaction conditions are 95°C for 15 minutes, 14 cycles (-0.5°C / cycle) of 94°C for 30 seconds, 63°C for 30 seconds, and 72°C for 45 seconds; then 30 cycles of 94°C for 30 seconds and 56°C for 30 seconds , 72°C for 45 seconds, and finally 72°C for 10 minutes;
[0042] (3) Purification of PCR products
[0043] Each reaction has a total volume of 5.6 μL. Add 4 μL of PCR product, then add 1.6 μL of SAP enzy...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention belongs to the technical field of biology, and particularly relates to an individualized medication gene testing reagent kit for a beta-receptor blocker. The individualized gene testingreagent kit for the beta-receptor blocker mainly comprises: (1) two pairs of CYP2D6*10 and ADRBB1(1165 G) [C] locus amplification and sequencing primers, (2) PCR amplification reagents, (3) a PCR product purification reagent, and (4) a DNA sequencing reagent. The reagent kit is used for detecting the loci of the beta-receptor blocker drug metabolizing enzyme and the receptor CYP2D6*10 and ADRBB1 (1165 G) [C] of the hypertension patient, uses the key technology for Sanger sequencing (the accuracy rate is more than 99.9%). The genotypes of the two loci are proved to be closely associated with the curative effect of medication of the beta-receptor blocker, so that the gene testing reagent kit can be used for guiding the hypertension patient in using the beta-receptor blocker drug reasonably and safely according to the testing result of the gene testing reagent kit.
Description
technical field [0001] The invention belongs to the field of biological technology, and in particular relates to a gene detection kit for detecting beta-receptor blockers for individualized medication. Background technique [0002] Statistics show that the prevalence of hypertension in my country is increasing year by year. By the end of 2014, the number of hypertensive patients in my country has reached 270 million, and the incidence rate is as high as 25.5%. However, the treatment rate is 41.1%, and the control rate is only 13.8%. The incidence of acute cardiovascular disease events, disability rates, and mortality rates have always remained high. Hypertension and related adverse events have become major public health problems that endanger the health of our people. Clinical drug results show that there are large individual differences in the efficacy and adverse reactions of hypertension medications. Although new drugs emerge in an endless stream, the blood pressure contro...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more